CAPS
Income statement / Annual
Last year (2024), Capstone Therapeutics Corp.'s total revenue was $44.88 M,
a decrease of 7.19% from the previous year.
In 2024, Capstone Therapeutics Corp.'s net income was -$2.56 M.
See Capstone Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$44.88 M |
$48.35 M |
$61.56 M |
$66.74 M |
$45.45 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$35.31 M
|
$38.74 M
|
$45.03 M
|
$50.43 M
|
$34.52 M
|
$39.00 K
|
$157.00 K
|
$205.00 K
|
$179.00 K
|
$157.00 K
|
| Gross Profit |
$9.57 M
|
$9.61 M
|
$16.53 M
|
$16.32 M
|
$10.94 M
|
-$39.00 K
|
-$157.00 K
|
-$205.00 K
|
-$179.00 K
|
-$157.00 K
|
| Gross Profit Ratio |
0.21
|
0.2
|
0.27
|
0.24
|
0.24
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.37 M
|
$1.04 M
|
$1.04 M
|
$1.18 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$762.00 K
|
$554.00 K
|
$641.00 K
|
$543.00 K
|
$1.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$39.00 K
|
-$157.00 K
|
-$205.00 K
|
-$179.00 K
|
-$157.00 K
|
| Selling, General & Administrative Expenses |
$10.21 M
|
$10.87 M
|
$12.54 M
|
$11.68 M
|
$8.54 M
|
$723.00 K
|
$397.00 K
|
$436.00 K
|
$364.00 K
|
$1.60 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.37 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$10.21 M
|
$10.87 M
|
$12.54 M
|
$11.68 M
|
$8.54 M
|
$723.00 K
|
$397.00 K
|
$1.48 M
|
$1.41 M
|
$2.78 M
|
| Cost And Expenses |
$45.51 M
|
$49.61 M
|
$57.57 M
|
$62.11 M
|
$43.06 M
|
$762.00 K
|
$554.00 K
|
$1.68 M
|
$1.58 M
|
$2.94 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$156.00 K
|
$70.00 K
|
$81.00 K
|
$4.00 K
|
| Interest Expense |
$1.48 M
|
$1.53 M
|
$895.00 K
|
$1.06 M
|
$710.00 K
|
$261.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$517.00 K
|
$306.00 K
|
$241.00 K
|
$386.00 K
|
$245.00 K
|
$39.00 K
|
$157.00 K
|
$205.00 K
|
$179.00 K
|
$157.00 K
|
| EBITDA |
-$121.00 K |
-$1.75 M |
$4.23 M |
$5.02 M |
$2.64 M |
-$723.00 K |
-$397.00 K |
-$1.48 M |
-$1.41 M |
-$2.78 M |
| EBITDA Ratio |
-0
|
-0.04
|
0.07
|
0.08
|
0.06
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.01
|
-0.03
|
0.06
|
0.07
|
0.05
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$5.30 M
|
-$2.33 M
|
-$895.00 K
|
-$279.00 K
|
-$710.00 K
|
-$261.00 K
|
-$248.00 K
|
-$111.00 K
|
-$81.00 K
|
-$24.00 K
|
| Income Before Tax |
-$5.94 M
|
-$3.59 M
|
$3.10 M
|
$4.36 M
|
$1.69 M
|
-$1.02 M
|
-$802.00 K
|
-$1.79 M
|
-$1.67 M
|
-$2.96 M
|
| Income Before Tax Ratio |
-0.13
|
-0.07
|
0.05
|
0.07
|
0.04
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$442.00 K
|
$234.00 K
|
$783.00 K
|
$436.00 K
|
-$8.49 M
|
-$24.00 K
|
-$49.00 K
|
-$36.00 K
|
-$56.00 K
|
-$192.00 K
|
| Net Income |
-$2.56 M
|
-$3.82 M
|
$2.32 M
|
$3.92 M
|
$10.46 M
|
-$2.07 M
|
-$380.00 K
|
-$1.76 M
|
-$663.00 K
|
-$2.77 M
|
| Net Income Ratio |
-0.06
|
-0.08
|
0.04
|
0.06
|
0.23
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-34.86 |
-36.39 |
14.69 |
49.46 |
107.6 |
-38.12 |
-6.99 |
-37.2 |
-16.22 |
-67.78 |
| EPS Diluted |
-34.86 |
-36.39 |
14.69 |
49.46 |
107.6 |
-38.12 |
-6.99 |
-37.2 |
-16.22 |
-67.78 |
| Weighted Average Shares Out |
$157.61 K
|
$157.61 K
|
$157.61 K
|
$79.28 K
|
$79.28 K
|
$54.38 K
|
$54.38 K
|
$47.17 K
|
$40.89 K
|
$40.89 K
|
| Weighted Average Shares Out Diluted |
$157.61 K
|
$157.61 K
|
$157.61 K
|
$79.28 K
|
$79.28 K
|
$54.38 K
|
$54.38 K
|
$47.17 K
|
$40.89 K
|
$40.89 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
